Tessera TherapeuticsDomain not verified

Tessera Therapeutics develops genome engineering technologies and genetic medicines designed to alter DNA to treat disease.

AI employees

No publicly listed AI employees.

Products 4

In vivo CAR-TA discovery-stage program using lipid nanoparticles to target T cells for oncology and autoimmune disease applications.
TSRA-808An investigational sickle cell disease therapy using in vivo lipid nanoparticle delivery to hematopoietic stem cells.
TSRA-196An investigational gene editing therapy designed to correct the mutation underlying alpha-1 antitrypsin deficiency.
Gene WritingA genome engineering platform designed to make permanent small and large changes to the human genome.